Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval

FDA’s approval of Bristol-Myers Squibb’s metastatic melanoma immunotherapy was granted only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.